Xiaohong R Yang1, Beena C R Devi2, Hyuna Sung3, Jennifer Guida3, Eliseos J Mucaki4, Yanzi Xiao3, Ana Best3, Lisa Garland5, Yi Xie3, Nan Hu3, Maria Rodriguez-Herrera3, Chaoyu Wang3, Kristine Jones5, Wen Luo5, Belynda Hicks5, Tieng Swee Tang2, Karobi Moitra3,6, Peter K Rogan4, Michael Dean3. 1. Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, NCI/NIH, Bethesda, Rockville, MD, USA. royang@mail.nih.gov. 2. Department of Radiotherapy, Oncology and Palliative Care, Sarawak General Hospital, Kuching, Sarawak, Malaysia. 3. Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, NCI/NIH, Bethesda, Rockville, MD, USA. 4. Department of Biochemistry, Schulich School of Medicine and Dentistry, University of Western Ontario, London, ON, Canada. 5. Cancer Genomics Research Laboratory, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, MD, USA. 6. Department of Biology, Trinity Washington University, Washington, DC, USA.
Abstract
PURPOSE: To characterize the spectrum of germline mutations in BRCA1, BRCA2, and PALB2 in population-based unselected breast cancer cases in an Asian population. METHODS: Germline DNA from 467 breast cancer patients in Sarawak General Hospital, Malaysia, where 93% of the breast cancer patients in Sarawak are treated, was sequenced for the entire coding region of BRCA1; BRCA2; PALB2; Exons 6, 7, and 8 of TP53; and Exons 7 and 8 of PTEN. Pathogenic variants included known pathogenic variants in ClinVar, loss of function variants, and variants that disrupt splice site. RESULTS: We found 27 pathogenic variants (11 BRCA1, 10 BRCA2, 4 PALB2, and 2 TP53) in 34 patients, which gave a prevalence of germline mutations of 2.8, 3.23, and 0.86% for BRCA1, BRCA2, and PALB2, respectively. Compared to mutation non-carriers, BRCA1 mutation carriers were more likely to have an earlier age at onset, triple-negative subtype, and lower body mass index, whereas BRCA2 mutation carriers were more likely to have a positive family history. Mutation carrier cases had worse survival compared to non-carriers; however, the association was mostly driven by stage and tumor subtype. We also identified 19 variants of unknown significance, and some of them were predicted to alter splicing or transcription factor binding sites. CONCLUSION: Our data provide insight into the genetics of breast cancer in this understudied group and suggest the need for modifying genetic testing guidelines for this population with a much younger age at diagnosis and more limited resources compared with Caucasian populations.
PURPOSE: To characterize the spectrum of germline mutations in BRCA1, BRCA2, and PALB2 in population-based unselected breast cancer cases in an Asian population. METHODS: Germline DNA from 467 breast cancerpatients in Sarawak General Hospital, Malaysia, where 93% of the breast cancerpatients in Sarawak are treated, was sequenced for the entire coding region of BRCA1; BRCA2; PALB2; Exons 6, 7, and 8 of TP53; and Exons 7 and 8 of PTEN. Pathogenic variants included known pathogenic variants in ClinVar, loss of function variants, and variants that disrupt splice site. RESULTS: We found 27 pathogenic variants (11 BRCA1, 10 BRCA2, 4 PALB2, and 2 TP53) in 34 patients, which gave a prevalence of germline mutations of 2.8, 3.23, and 0.86% for BRCA1, BRCA2, and PALB2, respectively. Compared to mutation non-carriers, BRCA1 mutation carriers were more likely to have an earlier age at onset, triple-negative subtype, and lower body mass index, whereas BRCA2 mutation carriers were more likely to have a positive family history. Mutation carrier cases had worse survival compared to non-carriers; however, the association was mostly driven by stage and tumor subtype. We also identified 19 variants of unknown significance, and some of them were predicted to alter splicing or transcription factor binding sites. CONCLUSION: Our data provide insight into the genetics of breast cancer in this understudied group and suggest the need for modifying genetic testing guidelines for this population with a much younger age at diagnosis and more limited resources compared with Caucasian populations.
Entities:
Keywords:
BRCA1/2; Breast cancer; Germline mutation; Malaysia; PALB2
Authors: Jacques Ferlay; Hai-Rim Shin; Freddie Bray; David Forman; Colin Mathers; Donald Maxwell Parkin Journal: Int J Cancer Date: 2010-12-15 Impact factor: 7.396
Authors: Lindsey A Torre; Freddie Bray; Rebecca L Siegel; Jacques Ferlay; Joannie Lortet-Tieulent; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2015-02-04 Impact factor: 508.702
Authors: Sven Rottenberg; Janneke E Jaspers; Ariena Kersbergen; Eline van der Burg; Anders O H Nygren; Serge A L Zander; Patrick W B Derksen; Michiel de Bruin; John Zevenhoven; Alan Lau; Robert Boulter; Aaron Cranston; Mark J O'Connor; Niall M B Martin; Piet Borst; Jos Jonkers Journal: Proc Natl Acad Sci U S A Date: 2008-10-29 Impact factor: 11.205
Authors: Lindsey A Torre; Rebecca L Siegel; Elizabeth M Ward; Ahmedin Jemal Journal: Cancer Epidemiol Biomarkers Prev Date: 2015-12-14 Impact factor: 4.254
Authors: Mark A DePristo; Eric Banks; Ryan Poplin; Kiran V Garimella; Jared R Maguire; Christopher Hartl; Anthony A Philippakis; Guillermo del Angel; Manuel A Rivas; Matt Hanna; Aaron McKenna; Tim J Fennell; Andrew M Kernytsky; Andrey Y Sivachenko; Kristian Cibulskis; Stacey B Gabriel; David Altshuler; Mark J Daly Journal: Nat Genet Date: 2011-04-10 Impact factor: 38.330
Authors: Wanqing Wen; Xiao-Ou Shu; Xingyi Guo; Qiuyin Cai; Jirong Long; Manjeet K Bolla; Kyriaki Michailidou; Joe Dennis; Qin Wang; Yu-Tang Gao; Ying Zheng; Alison M Dunning; Montserrat García-Closas; Paul Brennan; Shou-Tung Chen; Ji-Yeob Choi; Mikael Hartman; Hidemi Ito; Artitaya Lophatananon; Keitaro Matsuo; Hui Miao; Kenneth Muir; Suleeporn Sangrajrang; Chen-Yang Shen; Soo H Teo; Chiu-Chen Tseng; Anna H Wu; Cheng Har Yip; Jacques Simard; Paul D P Pharoah; Per Hall; Daehee Kang; Yongbing Xiang; Douglas F Easton; Wei Zheng Journal: Breast Cancer Res Date: 2016-12-08 Impact factor: 6.466
Authors: Eliseos J Mucaki; Natasha G Caminsky; Ami M Perri; Ruipeng Lu; Alain Laederach; Matthew Halvorsen; Joan H M Knoll; Peter K Rogan Journal: BMC Med Genomics Date: 2016-04-11 Impact factor: 3.063
Authors: Thales C Nepomuceno; Giuliana De Gregoriis; Francisco M Bastos de Oliveira; Guilherme Suarez-Kurtz; Alvaro N Monteiro; Marcelo A Carvalho Journal: Int J Mol Sci Date: 2017-08-31 Impact factor: 5.923
Authors: Mustapha Abubakar; Hyuna Sung; Devi Bcr; Jennifer Guida; Tieng Swee Tang; Ruth M Pfeiffer; Xiaohong R Yang Journal: Breast Cancer Res Date: 2018-09-18 Impact factor: 6.466
Authors: Vanessa Lattimore; Michael T Parsons; Amanda B Spurdle; John Pearson; Klaus Lehnert; Jan Sullivan; Caroline Lintott; Suzannah Bawden; Helen Morrin; Bridget Robinson; Logan Walker Journal: Breast Cancer Res Treat Date: 2020-10-28 Impact factor: 4.872